Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  AbbVie    ABBV

ABBVIE (ABBV)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

AbbVie : Investigators at AbbVie Detail Findings in Pharmaceutical and Biomedical Analysis (Use of ionic liquids as headspace gas chromatography diluents for...

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/05/2017 | 11:53pm CET

Investigators at AbbVie Detail Findings in Pharmaceutical and Biomedical Analysis (Use of ionic liquids as headspace gas chromatography diluents for the analysis of residual solvents in pharmaceuticals)

By a News Reporter-Staff News Editor at Biotech Week -- Investigators publish new report on Biotechnology - Pharmaceutical and Biomedical Analysis. According to news reporting originating in North Chicago, Illinois, by NewsRx journalists, research stated, "In this study, two ionic liquids (ILs), 1-butyl-3-methylimidazolium bis[(trifluoromethyl)sulfonyl]imide ([BMIM][NTf2]) and trihexyltetradecylphosphonium bis[(trifluoromethyl)sulfonyl]imide ([P-66614][NTf2]) were examined as contemporary diluents for residual solvent analysis using static headspace gas chromatography (SHS-GC) coupled with flame ionization detection (FID). ILs are a class of non-molecular solvents featuring negligible vapor pressure and high thermal stabilities."

The news reporters obtained a quote from the research from AbbVie, "Owing to these favorable properties, ILs have potential to enable superior sensitivity and reduced interference, compared to conventional organic diluents, at high headspace incubation temperatures. By employing the [BMIM][NTf2] IL as a diluent, a 25-fold improvement in limit of detection (LOD) was observed with respect to traditional HS-GC diluents, such as N-methylpyrrolidone (NMP). The established IL-based method demonstrated LODs ranging from 5.8 parts-per-million (ppm) to 20 ppm of residual solvents in drug substances. The optimization of headspace extraction conditions was performed prior to method validation. An incubation temperature of 140 degrees C and a 15 min incubation time provided the best sensitivity for the analysis. Under optimized experimental conditions, the mass of residual solvents partitioned in the headspace was higher when using [BMIM][NTf2] than NMP as a diluent. The analytical performance was demonstrated by determining the repeatability, accuracy, and linearity of the method. Linear ranges of up to two orders of magnitude were obtained for class 3 solvents. Excellent analyte recoveries were obtained in the presence of three different active pharmaceutical ingredients."

According to the news reporters, the research concluded: "Owing to its robustness, high throughput, and superior sensitivity, the HS-GC IL-based method can be used as an alternative to existing residual solvent methods."

For more information on this research see: Use of ionic liquids as headspace gas chromatography diluents for the analysis of residual solvents in pharmaceuticals. Journal of Pharmaceutical and Biomedical Analysis, 2017;145():879-886. Journal of Pharmaceutical and Biomedical Analysis can be contacted at: Elsevier Science Bv, PO Box 211, 1000 Ae Amsterdam, Netherlands. (Elsevier - www.elsevier.com; Journal of Pharmaceutical and Biomedical Analysis - www.journals.elsevier.com/journal-of-pharmaceutical-and-biomedical-analysis/)

Our news correspondents report that additional information may be obtained by contacting G.K. Webster, AbbVie Inc, North Chicago, IL 60064, United States. Additional authors for this research include T.D. Ho, J.L. Anderson and O. Nacham (see also Biotechnology - Pharmaceutical and Biomedical Analysis).

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1016/j.jpba.2017.05.033. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

Keywords for this news article include: North Chicago, Illinois, United States, North and Central America, Pharmaceutical and Biomedical Analysis, Biotechnology, AbbVie.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

(c) 2017 NewsRx LLC, source Health Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ABBVIE
11:21aABBVIE : reports more solid data for would-be psoriasis blockbuster
AQ
02/19ABBVIE : Increases Dividend and Announces New Stock Repurchase Program
AQ
02/19ABBVIE : Recognized as a FORTUNE 100 Best Company to Work For
AQ
02/18ABBVIE : Stocks’ Win Streak Extends to Six Days
AQ
02/17ABBVIE : Presents New Positive Late-Breaking Data from Two Phase 3 Psoriasis Tri..
PU
02/17ABBVIE : Presents New Late-Breaking Phase 2b Data on Upadacitinib in Atopic Derm..
PU
02/17ABBVIE : Announces New Phase 2 Data for Upadacitinib Showing Clinical and Endosc..
AQ
02/16JOHNSON & JOHNSON : Stocks stretch winning streak to 6 days despite turbulence
AQ
02/16ABBVIE : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS..
AQ
02/16ABBVIE : Announces New Phase 2 Data for Upadacitinib Showing Clinical and Endosc..
PR
More news
News from SeekingAlpha
07:41aMultiple Double-Digit Payout Increases In The First 2 Weeks Of February 
07:40aVoyager Therapeutics inks deal with AbbVie to develop anti-tau antibodies in .. 
02/19Healthcare In Transition 
02/19YOUR DAILY PHARMA SCOOP : AbbVie's Upadacitinib, Johnson & Johnson's Tremfya, Ce.. 
02/19VALUATION DASHBOARD : Healthcare - Update 
Financials ($)
Sales 2018 32 143 M
EBIT 2018 14 063 M
Net income 2018 10 260 M
Debt 2018 22 102 M
Yield 2018 2,64%
P/E ratio 2018 18,05
P/E ratio 2019 15,70
EV / Sales 2018 6,58x
EV / Sales 2019 5,98x
Capitalization 189 B
Chart ABBVIE
Duration : Period :
AbbVie Technical Analysis Chart | ABBV | US00287Y1091 | 4-Traders
Technical analysis trends ABBVIE
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 126 $
Spread / Average Target 6,1%
EPS Revisions
Managers
NameTitle
Richard A. Gonzalez Chairman & Chief Executive Officer
Azita Saleki-Gerhardt Senior Vice President-Operations
William J. Chase Chief Financial Officer & Executive Vice President
Michael E. Severino Chief Scientific Officer & Executive VP
Robert J. Alpern Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ABBVIE16.93%189 337
MERCK KGAA-8.06%13 280
KYOWA HAKKO KIRIN CO LTD5.76%12 664
JAZZ PHARMACEUTICALS PLC8.31%8 738
ZHANGZHOU PIENTZEHUANG PHARMACEUTICL LTD14.51%6 883
CONVATEC GROUP3.26%5 818